Safety and Tolerability of NV1FGF in Patients With Severe Peripheral Artery Occlusive Disease

Peripheral Arterial Occlusive Disease Clinical Trial

Official title:

A Phase I, Multi-Center, Open Label, Safety and Tolerability Study of Single and Repeated Administrations of Escalating Dose(s) of NV1FGF Administered by Intra-Muscular Injection in Patients With Severe Peripheral Artery Occlusive Disease

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01157156
• Other study ID #: TED10106
• Secondary ID: PM101
• Status: Completed
• Phase: Phase 1
• First received: July 2, 2010
• Last updated: July 2, 2010
• Start date: June 1999
• Est. completion date: September 2001

Study information

• Verified date: July 2010
• Source: Sanofi
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The primary objective is to evaluate safety and tolerability of single and repeated administrations of escalating doses of NV1FGF administered intramuscularly in patients with severe Peripheral Artery Occlusive Disease (PAOD), (Rutherford's Grade II, category 4 or Grade III, category 5 and 6).

Secondary objectives are:

• To determine the biological activity of NV1FGF on collateral artery development.

• To evaluate the activity of NV1FGF on hemodynamic and clinical parameters.

Description:

Screening period of 30 days before dosing. Patients receive a single administration or repeated (2) administrations (with a 2-week interval) of NV1FGF. Patients are then followed for a period of 6 months

Recruitment information / eligibility

• Status: Completed
• Enrollment: 51
• Est. completion date: September 2001
• Est. primary completion date: September 2001
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion criteria:

• Severe PAOD defined as Rutherford's Grade II, category 4 or Grade III, category 5 and 6

• Pain at rest for at least 2 weeks duration and/or trophic lesions for at least the previous 14 days with no signs of healing (no reduction in ulcer size or depth)

• Objective evidence of peripheral vascular disease (resting Ankle Brachial Index < 0.4 and/or resting Toe Brachial Index < 0.3 and/or metatarsal Peripheral Vascular Resistance flat or barely pulsatile in the diseased limb on 2 consecutive examinations performed at least 2 weeks apart)

• Angiographic demonstration of total occlusion of the affected limb of one or more of the iliac, superficial femoral, popliteal and/or one or more infrapopliteal arteries

• Poor candidate for surgical intervention or revascularization procedures (no tibial artery incontinuity as defined from mid-leg distance from the foot and no autologous tissue available)

Exclusion criteria :

• Previous or current history of malignant disease. Patients who had successful tumor resection more than 10 years prior to inclusion into the study and had no recurrence and patients who had curatively resected basal/squamous cancer of the skin were allowed for inclusion

• Abnormal chest X-ray with suspected malignant tumor presence

• Positive stool hemoccult (expect if due to hemorrhoids)

• Positive Prostate Specific Antigen for men with suspected malignant tumor presence

• Abnormal mammography for women with suspected malignant tumor presence

• Papanicolaou smear (for women) of Class IV or Class V characterization

• Proliferative retinopathy

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Arterial Occlusive Diseases
• Peripheral Arterial Disease
• Peripheral Arterial Occlusive Disease

Intervention

Drug:
• XRP0038 (NV1FGF)
Pharmaceutical form:solution Route of administration: intramuscular

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Sanofi

Countries where clinical trial is conducted

United States,  Finland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety assessment (adverse events, physical examination,vital signs,ECG, laboratory tests...)		12 weeks	Yes
Secondary	hemodynamic parameters (TcPO2, Ankle Brachial Index, Toe Brachial Index, pulse volume recording) and angiography		12 weeks	No
Secondary	ulcers healing assessment (length, width, type, depth)		12 weeks	No
Secondary	pain assessment (self-administered visual analog scale)		12 weeks	No